文献速递物质与行为成瘾心境障碍焦虑、强迫与应激相关障碍

孕期大麻使用障碍与共病行为及躯体疾病的关联

Association of Comorbid Behavioral and Medical Conditions With Cannabis Use Disorder in Pregnancy.
PubMed 文献 · JAMA Psychiatry · 2022-01-01

该研究分析2010至2018年35个州住院数据库中15至44岁孕妇的住院记录,比较伴与不伴大麻使用障碍(CUD)者的精神与躯体共病患病率。孕期住院中CUD比例从2010年的0.008升至2018年的0.02;仅伴CUD者在住院时抑郁、焦虑和恶心的患病率高于无物质使用障碍者。作者认为需加强筛查、预防和治疗,尤其针对CUD与精神障碍共病人群。

要点

  • 孕期住院中CUD比例从2010年的0.008升至2018年的0.02。
  • 仅伴CUD者住院时抑郁患病率升高0.089(95%CI 0.083-0.095)。
  • 仅伴CUD者住院时焦虑升高0.072(95%CI 0.066-0.076),恶心升高0.036(95%CI 0.033-0.040)。

核心结论

  • 孕期住院人群中CUD诊断患病率显著增长,伴CUD者住院时抑郁、焦虑、恶心及其他疾病患病率升高。
  • 作者认为需加强筛查、预防和治疗,尤其针对CUD与精神障碍共病人群。
  • 作者指出需开展关于孕期CUD决定因素与结局的研究,以帮助临床医生、政策制定者和患者做出知情决策。

研究设计与样本

  • 研究分析2010至2018年35个州医疗成本与利用项目州住院数据库的限制性出院数据,数据分析时间为2021年1月至8月。
  • 采用加权线性回归检验伴与不伴CUD诊断的住院患者精神与躯体疾病患病率差异。
  • 纳入15至44岁孕期住院患者,伴CUD诊断者与不伴CUD诊断者进行比较,并按共病物质使用障碍模式分层:其他SUD包括至少1种管制物质、其他SUD不包括管制物质、无其他SUD。

主要发现

  • 样本共纳入20,914,591例孕期住院,平均(SD)年龄28.24(5.85)岁。
  • 249,084例(1.19%)涉及CUD,20,665,507例(98.81%)不涉及CUD。
  • 孕期住院中CUD比例从2010年的0.008上升至2018年的0.02。
  • 无论是否共病其他SUD,伴与不伴CUD诊断的住院患者几乎所有医学和精神结局患病率均存在显著差异。
  • 仅伴CUD者住院时抑郁升高0.089(95%CI 0.083-0.095)、焦虑升高0.072(95%CI 0.066-0.076)、恶心升高0.036(95%CI 0.033-0.040),均高于无SUD住院者。

关键数值与推荐

  • CUD诊断依据住院出院记录识别,孕期住院中CUD比例为1.19%(249,084/20,914,591)。
  • 仅伴CUD者住院时抑郁患病率差值0.089(95%CI 0.083-0.095),焦虑差值0.072(95%CI 0.066-0.076),恶心差值0.036(95%CI 0.033-0.040),均与无SUD住院者比较。

临床怎么用

  • 作者认为需加强筛查、预防和治疗,尤其针对CUD与精神障碍共病人群。
  • 作者指出需开展关于孕期CUD决定因素与结局的研究,以帮助临床医生、政策制定者和患者做出知情决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Prenatal cannabis use continues to increase, yet studies of the demographic, psychiatric, and medical characteristics associated with cannabis use in pregnancy are limited by size and use of self-report, and often do not consider cannabis use disorder (CUD) or concomitant substance use disorders (SUDs). Understanding the factors associated with CUD in pregnancy is paramount for designing targeted interventions. OBJECTIVE: To examine the prevalence of co-occurring psychiatric and medical conditions of US pregnant individuals hospitalized with and without CUD by concomitant SUDs. DESIGN, SETTING, AND PARTICIPANTS: The study analyzed restricted hospital discharge data from the 2010 to 2018 Healthcare Cost and Utilization Project State Inpatient Databases in 35 states. Data were analyzed from January to August 2021. Weighted linear regressions tested whether the prevalence of psychiatric and medical conditions differed between individuals with and without a CUD diagnosis at hospitalization. Inpatient hospitalizations of pregnant patients aged 15 to 44 years with a CUD diagnosis were identified. Pregnant patients aged 15 to 44 years without a CUD diagnosis were identified for comparison. Patients were further stratified based on concomitant SUD patterns: (1) other SUDs, including at least 1 controlled substance; (2) other SUDs, excluding controlled substances; and (3) no other SUDs. EXPOSURES: CUD in pregnancy. MAIN OUTCOMES AND MEASURES: Prevalence of demographic characteristics, psychiatric disorders (eg, depression and anxiety), and medical conditions (eg, epilepsy and vomiting). RESULTS: The sample included 20 914 591 hospitalizations of individuals who were pregnant. The mean (SD) age was 28.24 (5.85) years. Of the total number of hospitalizations, 249 084 (1.19%) involved CUD and 20 665 507 (98.81%) did not. The proportion of prenatal hospitalizations involving CUD increased from 0.008 in 2010 to 0.02 in 2018. Analyses showed significant differences in the prevalence of almost every medical and psychiatric outcome examined between hospitalizations with and without CUD diagnoses, regardless of concomitant SUDs. Elevations were seen in depression (0.089; 95% CI, 0.083-0.095), anxiety (0.072; 95% CI, 0.066-0.076), and nausea (0.036; 95% CI, 0.033-0.040]) among individuals with CUD only at hospitalization compared with individuals with no SUDs at hospitalization. CONCLUSIONS AND RELEVANCE: Considerable growth was observed in the prevalence of CUD diagnoses among individuals hospitalized prenatally and in the prevalence of depression, anxiety, nausea, and other conditions in individuals with CUD at hospitalization. This study highlights the need for more screening, prevention, and treatment, particularly in populations with co-occurring CUD and psychiatric disorders. Research on the determinants and outcomes associated with CUD during pregnancy is needed to guide clinicians, policy makers, and patients in making informed decisions.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Meinhofer A, Hinde JM, Keyes KM, et al. Association of Comorbid Behavioral and Medical Conditions With Cannabis Use Disorder in Pregnancy. JAMA Psychiatry. 2022. PMID: 34730782. doi:10.1001/jamapsychiatry.2021.3193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。